Navigation Links
David Bagley Joins Histogen as President
Date:1/14/2009

Regenerative Medicine Company Poised for Product and Business Development Successes in the New Year

San Diego, CA (PRWEB) January 14, 2009-- Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn fibroblasts, announced today that David Bagley has joined the Company as President. Histogen welcomes Bagley following a year of rapid growth, with product launches, clinical evaluations and a new facility move on the horizon.

"With the launch of Histogen's first product, the creation of an aesthetics division, and talented new members joining the team in 2008, we've laid the groundwork for exciting progress in the coming year," said Dr. Gail Naughton, Histogen CEO and Chairman of the Board. "I am pleased to welcome David Bagley to Histogen, and believe his business experience and background in the field of tissue engineering will be a great asset to Histogen as we move forward."

David Bagley brings more than 20 years of cell biology and tissue engineering industry experience to Histogen. He has been a contributor to operational, scientific and engineering advancements in the development of several technologies including cell culture, tissue engineered and cell-based products for the treatment of multiple critical diseases, wound care and aesthetic product applications.

Most recently, Bagley served as Vice President and General Manager for Allergan Medical, Inc. with a focus on operations, technology, global distribution, quality and business disciplines. Prior to this, he held positions with Smith + Nephew/Advanced Tissue Sciences for over 12 years, where his latest position was Vice President of Technology and Logistics.

Previously, Bagley worked for Sigma Chemical Company where he was involved in the development and launch of several tissue culture product lines. Early in his career, he worked for HyClone Laboratories and Clonetics, both manufacturers and providers of cell culture products for various markets. Bagley has a B.S. degree in biology from Utah State University and a Master's degree in business from the American Graduate School of International Management in Arizona.

"Tissue engineering and cell-based products show a great deal of promise in the treatment of critical diseases and improving the lives of many people, however the development and launching of these complex products can be a challenge," said Bagley. "I am excited to join Histogen as President, and look forward to progressing these products and technologies to market."

About Histogen
Histogen, launched in 2007, seeks to redefine regenerative medicine by developing a series of high value products without the use of embryonic stem cells or animal products. Through Histogen's proprietary bioreactors that mimic the embryonic environment, newborn fibroblasts are encouraged to naturally produce the vital proteins and growth factors from which the company has developed its rich product portfolio. Histogen has two product families - ExceltrixTM, Histogen's human Extracellular Matrix (ECM) and ReGenicaTM, Histogen's proprietary liquid formula. The Company recently launched its first product - BioNuesisTM Human Stem Cell Culturing Kits - and announced the creation of its cosmeceutical venture - Histogen Aesthetics. For more information, please visit www.histogeninc.com.

###

Read the full story at http://www.prweb.com/releases/Histogen/Bagley/prweb1861514.htm


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. BrainCells Inc. Appoints David E. Thompson to Its Board of Directors
2. Prominent Urologist Dr. David B. Samadi Presents Breakthrough Robotic Surgery Techniques on OR Live Webcast
3. PercSys Names David Auth and Howard Palefsky to Its Board of Directors
4. David H. Murdock Research Institute Taps Waters for Laboratory Technology
5. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
6. Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board
7. David Hsia, Ph.D. Joins Kinex Pharmaceuticals Board of Directors
8. Trusted LASIK Surgeons Welcomes Leading LASIK Eye Surgery Expert, Inventor David Huang, M.D., Los Angeles, to Its Unique Lasik Directory Service
9. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
10. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
11. Omeros Appoints David A. Mann to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... June 27, 2017 , ... Indiana-based Xylogenics announced ... production and fermentation process. The efficiencies created by the newest strain design ... notably the ethanol industry wherein individual production plants are planning to invest upwards ...
(Date:6/26/2017)... ... ... Two new members were elected to the University City Science Center’s Board ... J Nowak Strategy and Michele Masucci, Ph.D., Vice President for Research Administration at Temple ... Kenneth L. Kring, and re-election of David P. Holveck and Richard P. Jaffe, as ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Academy of Model ... University Aviation Association (UAA), the unifying voice for collegiate aviation education, are launching ... teamwork, competition, and success through a STEM-based education platform. , Much like the ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... designating infertility as a disease, bringing new hope for prospective parents who are ... annual meeting to back the World Health Organization’s designation in hopes of changing ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
Breaking Biology News(10 mins):